
Please try another search
Shares of biotech firm Mersana Therapeutics (NASDAQ:MRSN) MRSN soared on Wednesday, closing up 69% to $18.19 per share.
Mersana reported positive interim results of an early-stage study of XMT-1536, an antibody-drug conjugate for treatment of patients with ovarian cancer. 10% of patients experienced complete remission after taking XMT-1536, while others achieved a 35% objective response rate. This means they saw tumor reduction by a pre-determined amount.
The drug candidate also has a good safety profile. CEO Anna Protopapas said the drug was “generally well tolerated”
Mersana is planning on reporting additional data from the study in the second half of 2020, which could be another big driver for the stock.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Ten days ago, we found using the Elliott Wave Principle (EWP) for the S&P 500: “As long as last week’s low at $4098 holds, the index can allow for a more direct rally to ideally...
A few years ago, I was studying the relationship between the major stock market indexes and their volatility indexes, and I came across and an intriguing phenomenon. The vast...
As one who tracks market sentiment, it still amazes me to watch it develop in real-time. And we see it quite well in the analyst community as well. Let me give you an example. Many...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.